NCT00701103View on ClinicalTrials.gov

Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001)

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 12, 2006

Primary Completion Date

December 1, 2009

Study Completion Date

December 1, 2009

Conditions
Solid TumorMultiple Myeloma
Interventions
DRUG

Dalotuzumab

IV infusion

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00701103 - Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001) | Biotech Hunter | Biotech Hunter